Corticosteroids in COVID-19: one size does not fit all

Athena Gogali, Chris Kyriakopoulos, Konstantinos Kostikas

Source: Eur Respir J, 57 (4) 2100224; 10.1183/13993003.00224-2021
Journal Issue: April
Disease area: Airway diseases, Respiratory critical care

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Athena Gogali, Chris Kyriakopoulos, Konstantinos Kostikas. Corticosteroids in COVID-19: one size does not fit all. Eur Respir J, 57 (4) 2100224; 10.1183/13993003.00224-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Dose-response effect of small particle vs standard size particle inhaled corticosteroids on severe asthma exacerbations by sex
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015

Acute asthma: large volume spacers are the best
Source: Eur Respir J 2005; 26: Suppl. 49, 504s
Year: 2005

Forced oscillation technique (FOT) reference values: Does one size fit all?
Source: Annual Congress 2012 - Predicting the future: the impact of reference values on a range of respiratory paramaters
Year: 2012

Predicting persistence of wheezing: one algorithm does not fit all
Source: Eur Respir J 2010; 35: 701-703
Year: 2010

Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Year: 2020

Treatment with inhaled a1-antitrypsin: a square peg in a round hole?
Source: Eur Respir J, 54 (5) 1901894; 10.1183/13993003.01894-2019
Year: 2019

Inhaled long-acting β2-agonist: aerosol particle size and bronchodilator response
Source: Eur Respir J 2005; 26: Suppl. 49, 126s
Year: 2005

Inhaled medication: which device for which patient?
Source: Eur Respir Monogr 2015; 69: 213-223
Year: 2015

Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014

Inhaled corticosteroids in COPD: the final verdict is…
Source: Eur Respir J, 52 (6) 1801940; 10.1183/13993003.01940-2018
Year: 2018

Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019

Getting it right: What does inhaler choice mean for patient outcomes?
Source: International Congress 2019 – Putting COPD patient needs first: Time for optimizing treatment and device selection
Year: 2019

Lung function in the elderly: time for new reference values?
Source: Annual Congress 2009 - Methodological aspects of asthma and COPD epidemiology
Year: 2009

Should asthma guidelines be rewritten for initial controller therapy: a 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and inhaled corticosteroids (ICS) in primary care
Source: Annual Congress 2008 - Rationale of self-education in asthma therapy
Year: 2008

Patient selection? One fits all (monotherapy versus combined therapy)?
Source: Sleep and Breathing Conference 2021
Year: 2021

Inhaled steroids and mortality in COPD: bias from unaccounted immortal time
Source: Eur Respir J 2004; 24: 190-191
Year: 2004

Inhaled antibiotics: a new tool?
Source: Annual Congress 2009 - Antibiotics and the lung
Year: 2009